Phase I trial of IMO 9200 in volunteers
Phase of Trial: Phase I
Latest Information Update: 18 May 2015
At a glance
- Drugs IMO 9200 (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Idera Pharmaceuticals
- 18 May 2015 Results published in the Idera Pharmaceuticals Media Release.
- 18 May 2015 Status changed from recruiting to completed, according to an Idera Pharmaceuticals media release.
- 07 Nov 2014 Idera Pharmaceuticals expects to select a lead autoimmune disease indication for further development of IMO-9200 in the first half of 2015, according to a media release.